Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Posted by George Bondi on Sep 19th, 2026

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) have received an average recommendation of “Moderate Buy” from the eleven research firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and ten have issued a buy recommendation on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $42.30.

Several equities research analysts have issued reports on the company. Bank of America restated a “buy” rating on shares of Syndax Pharmaceuticals in a report on Wednesday, August 5th. HC Wainwright cut their target price on shares of Syndax Pharmaceuticals from $40.00 to $38.00 and set a “buy” rating on the stock in a research note on Wednesday, August 5th. Weiss Ratings downgraded Syndax Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday. UBS Group decreased their target price on Syndax Pharmaceuticals from $37.00 to $33.00 and set a “buy” rating for the company in a research report on Friday, August 21st. Finally, JPMorgan Chase & Co. lowered their target price on shares of Syndax Pharmaceuticals from $44.00 to $40.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th.

Check Out Our Latest Research Report on Syndax Pharmaceuticals

Syndax Pharmaceuticals Trading Down 0.3%

NASDAQ SNDX opened at $17.62 on Monday. The firm has a market capitalization of $1.56 billion, a price-to-earnings ratio of -7.02 and a beta of 0.37. The company has a debt-to-equity ratio of 38.95, a quick ratio of 6.44 and a current ratio of 6.77. Syndax Pharmaceuticals has a one year low of $12.99 and a one year high of $25.59. The company’s 50 day moving average price is $20.15 and its 200 day moving average price is $21.12.

Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.10). The company had revenue of $72.79 million during the quarter, compared to analysts’ expectations of $79.36 million. Syndax Pharmaceuticals had a negative net margin of 87.52% and a negative return on equity of 372.94%. The company’s revenue for the quarter was up 91.8% compared to the same quarter last year. During the same period last year, the business earned ($0.83) earnings per share. On average, sell-side analysts predict that Syndax Pharmaceuticals will post -2.01 EPS for the current year.

Insider Buying and Selling

In related news, CEO Michael Metzger sold 32,375 shares of the firm’s stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $24.24, for a total value of $784,770.00. Following the sale, the chief executive officer directly owned 484,843 shares in the company, valued at $11,752,594.32. This trade represents a 6.26% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 4.80% of the company’s stock.

Institutional Trading of Syndax Pharmaceuticals

A number of institutional investors have recently made changes to their positions in SNDX. Tidal Investments LLC boosted its holdings in shares of Syndax Pharmaceuticals by 10.5% in the second quarter. Tidal Investments LLC now owns 72,212 shares of the company’s stock worth $1,579,000 after buying an additional 6,886 shares during the period. WINTON GROUP Ltd grew its stake in Syndax Pharmaceuticals by 642.7% during the 2nd quarter. WINTON GROUP Ltd now owns 76,500 shares of the company’s stock valued at $1,672,000 after acquiring an additional 66,200 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new position in shares of Syndax Pharmaceuticals in the 2nd quarter valued at about $73,000. Squarepoint Ops LLC increased its holdings in shares of Syndax Pharmaceuticals by 104.0% in the 2nd quarter. Squarepoint Ops LLC now owns 370,317 shares of the company’s stock valued at $8,095,000 after purchasing an additional 188,765 shares during the period. Finally, Arizona State Retirement System lifted its position in Syndax Pharmaceuticals by 2.9% in the 2nd quarter. Arizona State Retirement System now owns 23,120 shares of the company’s stock worth $505,000 after buying an additional 642 shares in the last quarter.

Syndax Pharmaceuticals Company Profile

(Get Free Report)

Syndax Pharmaceuticals, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering therapies for cancer and other serious diseases. The company’s research has centered on medicines that target disease-driving biological pathways, including genetically defined forms of leukemia and immune-related conditions.

Syndax’s lead product is Revuforj (revumenib), an oral menin inhibitor approved by the U.S. Food and Drug Administration for certain adults and children with relapsed or refractory acute leukemia involving a KMT2A translocation.